Acro Biomedical Co., Ltd. (ACBM) financial statements (2020 and earlier)
Company profile
| Business Address |
12175 VISIONARY WAY FISHERS, IN 46038 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| SIC | 79 - Amusement And Recreation Services (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 6/30/2019 TTM | 9/30/2018 | 9/30/2017 | 9/30/2016 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 1 | 37 | 3 | |||
| Cash and cash equivalents | 1 | 37 | 3 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,147 | 481 | ||||
| Inventory | 1,147 | 481 | ||||
| Prepaid expense | 330 | 31 | ||||
| Total current assets: | 1,478 | 548 | 3 | |||
| Noncurrent Assets | ||||||
| Other undisclosed noncurrent assets | 5 | |||||
| Total noncurrent assets: | 5 | |||||
| TOTAL ASSETS: | 1,483 | 548 | 3 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 7 | 1 | 7 | |||
| Taxes payable | 92 | |||||
| Other undisclosed accounts payable and accrued liabilities | (85) | 1 | 7 | |||
| Due to related parties | 141 | 36 | 10 | |||
| Other undisclosed current liabilities | 92 | |||||
| Total current liabilities: | 241 | 37 | 17 | |||
| Noncurrent Liabilities | ||||||
| Total liabilities: | 241 | 37 | 17 | |||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent | 1,242 | 511 | (15) | |||
| Common stock | 48 | 48 | 16 | |||
| Additional paid in capital | 869 | 558 | 61 | |||
| Retained earnings (accumulated deficit) | 325 | (94) | (92) | |||
| Total stockholders' equity: | 1,242 | 511 | (15) | |||
| TOTAL LIABILITIES AND EQUITY: | 1,483 | 548 | 3 | |||
Income statement (P&L) ($ in thousands)
| 6/30/2019 TTM | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|
| Revenues | 8,015 | 510 | |||
| Cost of revenue | (7,181) | (459) | |||
| Gross profit: | 833 | 51 | |||
| Operating expenses | (318) | (53) | (43) | ||
| Other undisclosed operating income | 87 | ||||
| Operating income (loss): | 516 | (2) | 43 | ||
| Nonoperating expense | (4) | ||||
| Interest and debt expense | (4) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 4 | ||||
| Income (loss) from continuing operations before income taxes: | 512 | (2) | 43 | ||
| Income tax expense | (92) | ||||
| Net income (loss): | 420 | (2) | 43 | ||
| Other undisclosed net loss attributable to parent | (87) | ||||
| Net income (loss) available to common stockholders, diluted: | 420 | (2) | (43) | ||
Comprehensive Income ($ in thousands)
| 6/30/2019 TTM | 9/30/2018 | 9/30/2017 | 9/30/2016 | ||
|---|---|---|---|---|---|
| Net income (loss): | 420 | (2) | 43 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 420 | (2) | 43 | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.